"How are innovative diagnostics companies securing valuebased rather than cost-based payment through personalized medicine? The panel will discuss how these innovators are building compelling clinical and economic evidence to support coverage and value-based payment from payers. Several case studies will be examined including a novel test for breast cancer, cardiology and an HIV theragnostic product."

Objective1: Review a number of models of diagnostic product and evidence development.

Objective2: Discuss the generalizability of these product attributes and development models to meet the needs of the payer community.

Objective3: "Identify the new opportunities and systemic challenges associated with identifying and defending the value proposition for diagnostic products."